febuxostat has been researched along with aluminum in 1 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (aluminum) | Trials (aluminum) | Recent Studies (post-2010) (aluminum) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 18,740 | 366 | 5,335 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hassan, SA; Khalil, WKB; Mowaad, NA; Sedik, AA; Shafey, HI | 1 |
1 other study(ies) available for febuxostat and aluminum
| Article | Year |
|---|---|
Febuxostat attenuates aluminum chloride-induced hepatorenal injury in rats with the impact of Nrf2, Crat, Car3, and MNK-mediated apoptosis.
Topics: Aluminum; Aluminum Chloride; Animals; Antioxidants; Apoptosis; Carnitine O-Acetyltransferase; Caspase 3; Febuxostat; Glutathione; Humans; Liver; Male; Molecular Docking Simulation; NF-E2-Related Factor 2; Oxidative Stress; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2023 |